CA-VELODYNE-LIDAR,-INC.
15.4.2021 01:02:08 CEST | Business Wire | Press release
Velodyne Lidar, Inc. (Nasdaq: VLDR, VLDRW) will demonstrate its groundbreaking sensor technology at Auto Shanghai 2021 – The 19th International Automobile Industry Exhibition (booth # 2.2H 6BC071) from April 21 to 28. Velodyne will highlight its technology leadership in lidar sensors and software which power autonomous solutions that advance safe, sustainable and accessible transportation and smart communities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005619/en/
Velodyne’s sensor and software solutions are uniquely suited to deliver flexibility, quality and performance to meet the needs of a wide range of industries. Velodyne will demonstrate lidar products designed for advanced driver assistance systems (ADAS), autonomous vehicles, robotics, smart city infrastructure, delivery, industrial and more.
“Velodyne Lidar is honored to be at Auto Shanghai 2021. Throughout our fourteen-year history, we have worked closely with customers in China in autonomous vehicles, next-generation consumer vehicles, mapping and robotics,” said Wei Weng, Executive Director of Asia, Velodyne Lidar. “China and Asia are valued markets to Velodyne and we are committed to delivering the highest quality lidar technologies to advance autonomous technologies in China. We remain committed to deepening our relationships and expand our partnerships with customers building the future of safer mobility and smarter cities.”
Velodyne has many important customers in China and maintains an office in Beijing. The company has partnered with Trunk.Tech to accelerate the commercialization of driverless trucks in China’s logistics market. Idriverplus is another important Velodyne customer headquartered in China. Idriverplus makes commercial autonomous vehicles, which include street cleaners, passenger cars and logistics vehicles. Velodyne has a long-standing relationship with Baidu , which is an investor in Velodyne. Baidu continues to use Velodyne’s sensors in its autonomy businesses.
Velodyne Highlights High Performance Sensor Technologies
Among the Velodyne products showcased at Auto Shanghai 2021 are:
Velodyne Alpha Prime™ , a next generation lidar sensor that utilizes Velodyne’s 360-degree surround view perception technology to power safe autonomous mobility. As a result of over ten years of lidar development and learning, the Alpha Prime is a sensor specifically made for autonomous driving in complex conditions for travel up to highway speeds. The combined 300-meter range, resolution and field of view in one sensor is designed to be a catalyst to drive the autonomous strategies of automotive and robotaxi companies.
Velarray H800 , a solid state lidar sensor architected for automotive grade performance and built using Velodyne’s breakthrough proprietary micro-lidar array architecture (MLA). With combined long-range perception and a broad field of view, the sensor is designed for safe navigation and collision avoidance in ADAS and autonomous mobility applications. It can enable advanced driver assistance features such as Adaptive Cruise Control (ACC), Lane Keep Assist (LKA), and Pedestrian Automatic Emergency Braking (PAEB). The Velarray H800’s compact, embeddable form factor is designed to fit neatly behind the windshield of a truck, bus or car, or be mounted seamlessly on the vehicle exterior.
Velarray M1600 , an innovative solid state lidar sensor designed to serve mobile robotic applications. The sensor is built using Velodyne’s MLA and provides outstanding near-field perception for safe navigation. The Velarray M1600 enables touchless mobile and last-mile delivery robots to operate autonomously and safely, without human intervention. This durable and compact sensor can be deployed in a wide variety of environments and weather conditions allowing nearly 365-day, 24/7 usage.
Velabit™ , Velodyne’s smallest sensor, which brings new levels of versatility and affordability to 3D lidar perception. This compact, mid-range lidar sensor is highly configurable for specialized use cases and can be embedded almost anywhere within vehicles, robots, unmanned aerial vehicles (UAVs) and infrastructure. Velabit advances Velodyne’s mission to make high-quality 3D lidar sensors readily accessible to everyone.
Vella™ , Velodyne’s breakthrough ADAS software based on the directional view Velarray sensor. Superior to existing approaches that utilize camera+radar, Vella can revolutionize advanced driver assistance functionalities currently on the market, including Adaptive Cruise Control, Lane Keep Assist and Pedestrian Automated Emergency Braking (PAEB). A Velodyne white paper and video examine nighttime tests conducted by Velodyne of its lidar-based PAEB system that uses the Velarray H800 sensor and Vella compared to a highly-rated system using camera+radar technology. In these conditions, the camera+radar-based system failed in all five scenarios while the lidar-based system avoided a crash in every situation tested.
About Velodyne Lidar
Velodyne Lidar (Nasdaq: VLDR, VLDRW) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com .
Forward Looking Statements
This press release contains "forward looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words "estimates," "projected," "expects," "anticipates," "forecasts," "plans," "intends," "believes," "seeks," "may," "will," “can,” "should," "future," "propose" and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne's control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include the uncertain impact of the COVID-19 pandemic on Velodyne's and its customers' businesses; Velodyne's ability to manage growth; Velodyne's ability to execute its business plan; uncertainties related to the ability of Velodyne's customers to commercialize their products and the ultimate market acceptance of these products; uncertainties regarding government regulation and adoption of lidar; the rate and degree of market acceptance of Velodyne's products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne's current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne's intellectual property; and general economic and market conditions impacting demand for Velodyne's products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005619/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
